Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase afteR AllogeneiC hematopoietic stem celL transplantation with fEcal microbiota transfer (HERACLES)

Trial Profile

Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase afteR AllogeneiC hematopoietic stem celL transplantation with fEcal microbiota transfer (HERACLES)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2018

At a glance

  • Drugs Maa-T-013 (Primary)
  • Indications Graft-versus-host disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms HERACLES
  • Sponsors MaaT Pharma
  • Most Recent Events

    • 21 Jun 2018 According to a MaaT Pharma media release, the company has received authorization from the French regulatory authorities to start this trial. The company is planning to treat the first patient in the trial in the near future.
    • 21 Mar 2018 Dates are not mentioned in EudraCT please update once more information become available.
    • 17 Mar 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top